Andexxa

Andexxa

Serious injuries, including death, that survivors don’t even know they have suffered.

Why the Vigna Law Group for your Andexxa injury claim?

Talk to Vigna Law Group, a national litigation firm that focuses on harmful drugs, including DEPO-PROVERA and Andexxa. Dr. Greg Vigna represents women with the Ben Martin Law Group, a national pharmaceutical injury law firm in Dallas, Texas. The attorneys are product liability and medical malpractice attorneys who represent clients with neurological injuries nationwide on a non-exclusive basis.

01.

Your initial contact will always be with a nurse or an attorney.

02.

Your medical records will be carefully reviewed by experienced nurses and physicians.

03.

Your case will be led by Dr. Greg Vigna and the Vigna Law Group, a team of doctors and legal experts.

Complete the form, and Dr. Vigna or one of our experts will review your information and get back to you promptly.

Causes of Injury

“Andexxa was the antidote for major bleeding complications caused by Xarelto and Eliquis, both intracerebral and intra-abdominal. Andexxa stopped the bleeding but caused blood clots 2.1x more than usual care and 2.8x more deaths than usual care.” Greg Vigna, MD, JD, national pharmaceutical injury attorney.

Vigna Law Group announces clinical criteria for case evaluation:

Suffered a major bleed from Xarelto or Eliquis?

Suffered subsequent blood clots after a major bleed associated with Xarelto or Eliquis?

Death caused by thrombotic complications after a major bleed associated with Xarelto or Eliquis?

Thrombotic complications after a major bleed associated with Xarelto or Eliquis?

“This is a terrible drug, and clearly AstraZeneca has many questions to answer. How could a drug that causes twice as many thrombotic complications with routine use, and nearly 3x the risk of death, get into the veins of patients who are seriously ill with major bleeding complications?”

Dr. Vigna

Read The Latest Andexxa News

FDA Orders Withdrawal of Andexxa: Doubled Risk of Fatal Blood Clots Leads to Market Removal

12/18/2025

“The FDA’s decision to withdraw Andexxa from the market underscores a critical failure in post-market surveillance and patient safety,” states Greg Vigna, MD, JD, national medical malpractice attorney. The U.S. Food and Drug Administration announced on December 18, 2025, that Andexxa (coagulation factor Xa recombinant, inactivated-zhzo) will be withdrawn from the U.S. market following alarming […]